Boehringer Ingelheim v. Mylan Pharmaceuticals, Inc. (N.D. W.Va.): Represented Boehringer Ingelheim in a patent infringement suit arising from defendants’ submissions of ANDAs to the FDA seeking approval to manufacture and sell generic versions of Boehringer’s TRADJENTA® (linagliptin) and JENTADUETO® (linagliptin and metformin hydrochloride) tablets used to treat type II diabetes that resulted in a Plaintiff-friendly settlement prior to trial after a decade of litigation.
Eli Lilly & Co. v. Compounders (D. Az./S.D. Cal./D. Col./D.D.C./M.D. Fla./D. Haw./S.D. Ind./N.D. Ohio/S.D. Ohio/S.D. Tex./W.D. Wash.): Secured permanent injunctions in multiple litigations concerning violations of the Lanham Act and state prohibitions on deceptive trade practices. The cases involve the defendants’ use of Lilly’s MOUNJARO® and ZEPBOUND® trademarks to market and sell their own, non-FDA approved drugs, as well as promotion of the sale of those drugs by falsely representing them to prospective customers as having the same indicia of safety, effectiveness and quality as Lilly’s medicines.
In re Certain Vehicle Telematics, Fleet Management, and Driver Safety Systems, Devices, and Components Thereof (USITC): Represented Samsara in a patent infringement, false advertising, trade secret misappropriation, unfair competition, and state-law tort claims concerning Samsara’s and Motive’s internet-of-things and artificial intelligence technologies.
